Enveric Biosciences Inc (ENVB) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Return on Equity, Quarterly Results, Trends, Rankings, Statistics
What is ROE for Enveric Biosciences Inc in the second quarter 2026?
Enveric Biosciences Inc recorded a cumulative net loss of $-9 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -168.05%.
Within the Major Pharmaceutical Preparations industry 303 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3684 to 3750.
In a market increasingly focused on mental health solutions, Enveric Biosciences (NASDAQ: ENVB), a leading biotechnology firm headquartered in Cambridge, Massachusetts, has reported its financial and operational results for the third quarter of 2024. With a commitment to pioneering innovative neuroplastogenic small-molecule therapeutics, the company continues to make significant strides in treating conditions such as depression, anxiety, and addiction disorders.For the quarter ended September 30, 2024, Enveric s financial performance showcased the company s potential for growth amidst an evolving therapeutic landscape. The firm reported an increase in research and development expenditures, reflecting its ongoing investment in innovative product candidates, particularly EB-003. This novel compound aims to leverage neuroplasticity to address mental health disorders, an area of increasing urgency given the global mental health crisis exacerbated by recent societal stresses.
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results CAMBRIDGE, Mass. Enveric Biosciences (NASDAQ: ENVB) continues to make significant strides in the biotechnology sector, particularly in developing novel neuroplastogenic small-molecule therapeutics aimed at tackling some of the most pressing mental health challenges, including depression, anxiety, and addiction disorders. As part of its commitment to innovation, the company recently provided a corporate update alongside its financial performance for the third quarter of 2024, ending September 30. Progress in Drug DevelopmentThe highlight of Enveric’s Q3 report was the promising progress in the development of its lead candidate, EB-003. This neuroplastogen has shown considerable potential in preclinical studies, demonstrating both pharmacological efficacy and safety. Results from recent studies confirmed EB-003 s selective action on desired serotonergic neuroreceptors, which is a critical factor in addressing the intricacies of mood and addiction disorders. The positive results are pivotal, offering new avenues for treatment options in a space that desperately requires innovative therapies.
Enveric Biosciences Expands Patent Protection, Advancing Neuropsychiatric Innovation CAMBRIDGE, Mass. Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology company focused on the development of innovative neuroplastogens for treating neuropsychiatric disorders, has announced a significant expansion of its patent protection. The company recently secured five additional patents and obtained allowances for three more applications from the United States Patent and Trademark Office (USPTO), enhancing its already robust intellectual property portfolio surrounding its EVM301 product line.This strategic move not only underscores Enveric s commitment to advancing its research and development capabilities but also positions the company favorably within an increasingly competitive biotech landscape. By broadening its patent coverage, Enveric is protecting its proprietary molecules against potential competitors while simultaneously creating a stronger foundation for future commercialization efforts.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
